FDA Approves KRYSTEXXA^® (Pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon Therapeutics plc announced that the FDA has approved the supplemental Biologics License Application expanding the labeling to include KRYSTEXXA® injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy.